Italia markets open in 7 hours 40 minutes

Arrowhead Pharmaceuticals, Inc. (0HI3.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
30,14+0,88 (+3,02%)
Alla chiusura: 06:49PM GMT
Schermo intero
Chiusura precedente29,25
Aperto0,00
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno0,00 - 0,00
Intervallo di 52 settimane
Volume4.600
Media VolumeN/D
Capitalizzazione29,574M
Beta (5 anni mensile)1,41
Rapporto PE (ttm)N/D
EPS (ttm)-1,08
Prossima data utili31 gen 2023 - 06 feb 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones

    Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement NEW YORK and PASADENA, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Arrowhead today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals (Nasd